ALCON INC. INTERIM FINANCIAL REPORT | INDEX | Page | | --- | --- | | Operating Performance | 2 | | Liquidity and Capital Resources | 7 | | Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) | | | Consolidated Income Statement | 10 | | Consolidated Statement of Comprehensive Income | 11 | | Consolidated Balance Sheet | 12 | | Consolidated Statement of Changes in Equity | 13 | | Consolidated Statement of Cash Flows | 14 | | Notes to Condensed Consolidated Interim Financial Statement ...

Core Viewpoint - Analysts expect Alcon to report quarterly earnings of $0.76 per share, reflecting a year-over-year decline of 2.6%, with revenues projected at $2.51 billion, an increase of 2.7% from the previous year [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1][2] Key Metrics Projections - Analysts estimate 'Net Sales- Total Surgical' to be $1.38 billion, representing a year-over-year increase of 2.8% [3] - The forecast for 'Net Sales- Total Vision Care' is $1.14 billion, indicating a year-over-year change of 2.7% [4] - 'Net Sales- Total Surgical- Consumables' is projected to reach $717.01 million, reflecting a 4.5% increase from the prior year [4] - 'Net Sales- Total Surgical- Equipment/other' is expected to be $223.04 million, showing a 1.8% year-over-year change [4] - 'Net Sales- Total Vision Care- Contact lenses' is anticipated to be $693.41 million, indicating a 3.3% increase from the previous year [5] - 'Net Sales- Total Vision Care- Ocular health' is projected at $441.87 million, reflecting a year-over-year change of 1.6% [5] - 'Net Sales- Total Surgical- Implantables' is expected to reach $435.74 million, indicating a 0.6% increase from the prior year [6] - The consensus for 'Revenues- Other revenues' stands at $17.50 million, reflecting a significant year-over-year increase of 16.7% [6] - 'Net sales by region- International' is projected to be $1.39 billion, indicating a 7.4% increase from the previous year [6] Stock Performance - Alcon shares have increased by 6.8% over the past month, compared to an 11.3% increase in the Zacks S&P 500 composite, with a Zacks Rank of 3 (Hold), suggesting expected performance in line with the overall market [7]

Company Overview - Alcon Inc. has launched the Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in the U.S., utilizing ENLIGHTEN NXT Optical technology for superior light utilization and minimal light scatter [1][5] - The company has a market capitalization of $45.76 billion and has consistently beaten earnings expectations over the last four quarters, with an average surprise of 5.92% [4] Product Details - The Clareon PanOptix Pro is designed to enhance near and intermediate vision, offering a range of powers from +6.0 to +34.0 diopters, and includes features for blue light and ultraviolet filtering [6] - The lens is expected to recover 50% of light lost to scatter, improving visual clarity post-cataract surgery [5] Market Position and Trends - Alcon's Surgical segment is benefiting from a diverse product portfolio and strong demand for presbyopia-correcting IOLs, maintaining a leading market share [3] - Following the product launch, Alcon's stock experienced a slight decline of 0.1%, but has seen a 10.5% increase over the past year, outperforming the industry [2] Industry Prospects - The global intraocular lens market was valued at $4.0 billion in 2022 and is projected to grow at a compound annual growth rate of 6.3%, reaching $6.0 billion by 2029, driven by an increase in cataract surgeries and an aging population [10] Recent Developments - Alcon's Clareon Vivity IOL received CE Mark approval, and the company has entered an agreement to acquire LENSAR, enhancing its capabilities in advanced laser solutions for cataract treatment [11][12] - The PanOptix Pro will be available in select U.S. practices, with broader availability expected in May and additional markets rolling out by late 2025 [7][8]

This hugely promising market, while witnessing rapid advancements, is still in the early stages of development and the prospects are majorly untapped. Companies with a strong presence in the ophthalmic market, such as Alcon Inc. (ALC) , Glaukos Corporation (GKOS) and Regeneron Pharmaceuticals, Inc. (REGN) , are well- positioned to leverage this prospect, making them promising investment opportunities. Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popu ...

Alcon (ALC) shares ended the last trading session 6% higher at $96.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.1% loss over the past four weeks.Alcon scored a strong price increase driven by the optimism surrounding the company’s aggressive move on the M&A front. The company recently acquired a majority interest in Aurion Biotech, Inc. - a clinical-stage company developing advanced cell therapies to treat ...

Alcon (ALC) recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) technology, has received CE Mark approval. The lens, made from Alcon's advanced Clareon material, is set for commercial rollout across Europe in early second-quarter 2025, expanding visual possibilities for patients.This milestone highlights Alcon's commitment to enhancing vision care, offering patients a premium presbyopia-correcting solution. The introduction of Clareon Vivity IOL marks ...

Alcon (ALC) and LENSAR, Inc. (LNSR) , a global medical technology company focused on advanced laser solutions for the treatment of cataracts, recently entered into a definitive merger agreement. Per the agreement, Alcon will acquire LENSAR’s ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system. Alcon anticipates to close the transaction by mid-to-late 2025. The latest acquisition is expected to bolster its Surgical business.Alcon Stock’s Lik ...

Core Viewpoint - Alcon has announced a definitive merger agreement to acquire LENSAR, enhancing its portfolio in cataract surgery technology with LENSAR's advanced laser solutions and proprietary software [1][2][3] Financial Details - Alcon will acquire all outstanding shares of LENSAR for $14.00 per share in cash, totaling approximately $356 million, with potential additional payments of up to $2.75 per share based on performance milestones [2] - The total potential consideration could reach $16.75 per share, representing a 24% premium to LENSAR's 30-day volume-weighted average price (VWAP) and a 47% premium to its 90-day VWAP, assuming milestones are met [2] Strategic Implications - The acquisition aims to leverage LENSAR's next-generation technologies to improve the efficiency and precision of cataract surgeries globally, addressing the high prevalence of visually significant astigmatism [3][4] - Alcon's CEO emphasized the opportunity to expand the reach of advanced femtosecond laser technology to more surgeons worldwide, enhancing surgical outcomes [3] Market Context - There are over 5 million cataract procedures performed annually in the U.S. and approximately 32 million globally, indicating a significant market for the enhanced technology [3] - LENSAR's ALLY Robotic Cataract Laser System™ is designed to improve operational efficiencies and reduce overhead in cataract surgery, which aligns with the growing demand for advanced surgical solutions [11] Transaction Timeline - The merger is expected to close in mid-to-late 2025, pending regulatory approvals and stockholder consent from LENSAR [4]

Core Insights - Alcon's Surgical business is benefiting from a diverse portfolio and incremental innovation, while Vision Care is experiencing solid growth driven by strong sales of contact lenses and ocular health products [1][3][6] Surgical Business Performance - Alcon's technology leads the market, with every three advanced intraocular lenses (IOLs) implanted globally being Alcon products, and one out of two premium IOLs being from Alcon [3] - The surgical segment reported a 5% year-over-year revenue growth in Q4 2024, driven by strong international demand for IOLs, consumables, and equipment [3] New Product Innovations - Alcon leads the market in Presbyopia-correcting Intraocular Lenses (PCIOLs) with over 60% global share and more than 80% in the U.S., supported by strong demand for products like PanOptix and Vivity [4] - Upcoming product launches include the next-generation PanOptix and the UNITY VCS, along with innovations like the PanOptix Pro PCIOL and the Voyager Direct Selective Laser Trabeculoplasty device [5] Vision Care Growth - Alcon's Vision Care segment closed Q4 with a 7% year-over-year growth, successfully executing strategies in fast-growing market segments [6] - The launch of PRECISION7, a weekly replacement lens, targets the $3.8 billion reusable lens market, while the Systane family of artificial tears continues to perform strongly [7] Industry Challenges - Alcon faces macroeconomic pressures, including inflation in electronic components, freight, labor, and supply chain challenges, which are expected to persist into 2025 [10] - The ophthalmology industry is highly competitive, with Alcon facing intense competition from both large and small manufacturers, as well as potential disruptions from pharmaceutical companies [11][12] Financial Performance - Alcon's market capitalization stands at $43.97 billion, with earnings surpassing estimates in three of the last four quarters, delivering an average surprise of 5.9% [2] - The Zacks Consensus Estimate for Alcon's 2025 earnings per share has decreased by 2.1% to $3.23, while revenues are projected to rise by 4.9% to $10.32 billion [13]

Alcon Inc. (ALC) gains on strong market share gains. The company’s broad pipeline and focus on research and innovation are impressive. Yet, a challenging international market with geopolitical pressure concerns and a tough competitive landscape are threats. The stock presently carries a Zacks Rank #3 (Hold).Major Factors Driving ALC SharesWithin the Surgical business, of late, the company’s flagship lenses, Vivity and PanOptix, continue to lead the category in the United States and around the world. The Sur ...